Evidence map›Paper›PMID 28250739›Full record

ReviewNeural regeneration research2017

Platelet-rich plasma, an adjuvant biological therapy to assist peripheral nerve repair.

Mikel Sánchez, Ane Garate, Diego Delgado, Sabino Padilla

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Neural regeneration research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Mikel SánchezArthroscopic Surgery Unit, Hospital Vithas San José, Vitoria-Gasteiz, Spain; Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-9992-6927
Ane GarateDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.
Diego DelgadoDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-0494-0804
Sabino PadillaBTI Biotechnology Institute, Vitoria-Gasteiz, Spain.
University of Minnesota · USBTI Biotechnology Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapies such as direct tension-free microsurgical repair or transplantation of a nerve autograft, are nowadays used to treat traumatic peripheral nerve injuries (PNI), focused on the enhancement of the intrinsic regenerative potential of injured axons. However, these therapies fail to recreate the suitable cellular and molecular microenvironment of peripheral nerve repair and in some cases, the functional recovery of nerve injuries is incomplete. Thus, new biomedical engineering strategies based on tissue engineering approaches through molecular intervention and scaffolding offer promising outcomes on the field. In this sense, evidence is accumulating in both, preclinical and clinical settings, indicating that platelet-rich plasma products, and fibrin scaffold obtained from this technology, hold an important therapeutic potential as a neuroprotective, neurogenic and neuroinflammatory therapeutic modulator system, as well as enhancing the sensory and motor functional nerve muscle unit recovery.

Indexed as

axons, platelet-rich plasmabiomoleculesfibrinintraneuralmicroenvironmentperineuralperipheral nerve injuries (PNI)scaffoldSchwann cells

Identifiers

PMID28250739
PMCPMC5319232
OpenAlexW2580806150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.